This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Long-term collection of patient-reported outcome data in oncology trials: Important and feasible

Credit: CC0 Public Domain

Patient-reported outcome (PRO) data are collected in oncology trials to determine patients' perspectives of cancer treatment—unfortunately often too briefly, for example only up to the point when an X-ray shows tumor growth and treatment is discontinued. As a result, it is not possible, for example, to reliably assess the impact on patients' lives of disease progression seen on X-rays or the long-term side effects of cancer treatment.

The reasons given for this are organizational difficulties or patients' lack of interest in long-term follow-up. But is this really the case?

These and similar questions were discussed at a roundtable in 2020 that brought together 16 stakeholders from academia, , patient representatives, international regulatory agencies, HTA bodies, and the pharmaceutical industry. The German Institute for Quality and Efficiency in Health Care (IQWiG) was represented by Beate Wieseler, Head of the Drug Assessment Department. The results have now been published in a scientific journal.

A clear plan and good explanations needed

All parties agreed that it is important to understand the long-term effects of treatments on patients in —even after treatment has been discontinued. This information is important for decisions by regulators, payers, physicians and patients.

To make the best use of PRO data collected after the study treatment has ended, clinical trial sponsors must define clear research questions before begins. Anything less is unethical and a waste of resources and patients' valuable time.

According to patient representatives, patients are willing to invest time in the collection of PRO data if it is made clear why their input is valuable. This shows that the long-term collection of such data is not an unrealistic academic pipe dream, but is feasible with good planning—and not at all against the interests of patients.

The work is published in the journal Value in Health.

More information: Bellinda L. King-Kallimanis et al, Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials, Value in Health (2023). DOI: 10.1016/j.jval.2023.06.019

Citation: Long-term collection of patient-reported outcome data in oncology trials: Important and feasible (2023, August 4) retrieved 21 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Supplemental indications in drug approval: Often no proof of added value, says researcher


Feedback to editors